317 related articles for article (PubMed ID: 10698338)
1. The covalent interaction of C3 with IgG immune complexes.
Vivanco F; Muñoz E; Vidarte L; Pastor C
Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
[TBL] [Abstract][Full Text] [Related]
2. The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.
Muñoz E; Vidarte L; Casado MT; Pastor C; Vivanco F
Int Immunol; 1998 Feb; 10(2):97-106. PubMed ID: 9580208
[TBL] [Abstract][Full Text] [Related]
3. Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1.
Vidarte L; Pastor C; Mas S; Blázquez AB; de los Rios V; Guerrero R; Vivanco F
J Biol Chem; 2001 Oct; 276(41):38217-23. PubMed ID: 11447230
[TBL] [Abstract][Full Text] [Related]
4. A small domain (6.5 kDa) of bacterial protein G inhibits C3 covalent binding to the Fc region of IgG immune complexes.
Muñoz E; Vidarte L; Pastor C; Casado M; Vivanco F
Eur J Immunol; 1998 Aug; 28(8):2591-7. PubMed ID: 9710236
[TBL] [Abstract][Full Text] [Related]
5. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.
Edberg JC; Tosic L; Wright EL; Sutherland WM; Taylor RP
J Immunol; 1988 Dec; 141(12):4258-65. PubMed ID: 3198918
[TBL] [Abstract][Full Text] [Related]
7. How immune complexes from certain IgG NAbs and any F(ab')₂ can mediate excessive complement activation.
Lutz HU
Adv Exp Med Biol; 2012; 750():186-96. PubMed ID: 22903675
[TBL] [Abstract][Full Text] [Related]
8. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
9. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
[TBL] [Abstract][Full Text] [Related]
10. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
Gadd KJ; Reid KB
Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
[TBL] [Abstract][Full Text] [Related]
11. Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.
Theofilopoulos AN; Dixon FJ; Bokisch VA
J Exp Med; 1974 Oct; 140(4):877-94. PubMed ID: 4139225
[TBL] [Abstract][Full Text] [Related]
12. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
14. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
Baatrup G; Svehag SE; Jensenius JC
Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
[TBL] [Abstract][Full Text] [Related]
15. Breakdown of C3 covalently bound to F(ab')2 immune complexes after complement activation by the alternative pathway.
Antón LC; Alcolea JM; Marqués G; Sánchez-Corral P; Vivanco F
Complement; 1986; 3(2):53-62. PubMed ID: 3769463
[TBL] [Abstract][Full Text] [Related]
16. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation.
Jelezarova E; Luginbuehl A; Lutz HU
J Biol Chem; 2003 Dec; 278(51):51806-12. PubMed ID: 14527961
[TBL] [Abstract][Full Text] [Related]
17. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
18. Interaction of C3 and C3b with immunoglobulin G.
Kulics J; Rajnavölgyi E; Füst G; Gergely J
Mol Immunol; 1983 Aug; 20(8):805-10. PubMed ID: 6621540
[TBL] [Abstract][Full Text] [Related]
19. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes.
Kávai M; Rasmussen JM; Baatrup G; Zsindely A; Svehag SE
Scand J Immunol; 1988 Jul; 28(1):123-8. PubMed ID: 2969612
[TBL] [Abstract][Full Text] [Related]
20. Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation.
Sahu A; Pangburn MK
J Biol Chem; 1994 Nov; 269(46):28997-9002. PubMed ID: 7961863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
